SG301-SC / Sumgen Biotech - LARVOL DELTA

A Study of Anti-CD38 Monoclonal Antibody (SG301) Subcutaneous Injection in Children With Nephrotic Syndrome With Frequent Relapses or Steroid Dependence (clinicaltrials.gov) - P2 | N=30 | Recruiting | Sponsor: Mao Jianhua | Not yet recruiting ➔ Recruiting

Enrollment open • Glomerulonephritis • Nephrology • Renal Disease

A Study of Anti-CD38 Monoclonal Antibody (SG301) Subcutaneous Injection in Children With Nephrotic Syndrome With Frequent Relapses or Steroid Dependence (clinicaltrials.gov) - P2 | N=30 | Not yet recruiting | Sponsor: Mao Jianhua

New P2 trial • Glomerulonephritis • Nephrology • Renal Disease

A Clinical Study to Evaluate the Preliminary Efficacy and Safety of SG301 SC Subcutaneous Injection in Children with Frequently Relapsing or Steroid-Dependent Nephrotic Syndrome (ChiCTR) - P=N/A | N=30 | Not yet recruiting | Sponsor: Children's Hospital,Zhejiang University School of Medicine; Children's Hospital,Zhejiang University School of Medicine

New trial • Glomerulonephritis • Nephrology • Renal Disease

SG301-SC Injection Safety Study in Subjects With Systemic Lupus Erythematosus (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: Hangzhou Sumgen Biotech Co., Ltd. | Trial completion date: Oct 2025 ➔ Oct 2026 | Trial primary completion date: May 2025 ➔ May 2026

IO biomarker • Trial completion date • Trial primary completion date • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus